Trial Profile
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Asunercept (Primary) ; Atezolizumab (Primary) ; Idasanutlin (Primary) ; Palbociclib (Primary) ; Temsirolimus (Primary) ; Vismodegib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms N2M2
- 26 Sep 2023 Status changed from recruiting to completed.
- 26 Sep 2023 Status changed from recruiting to completed.
- 06 Apr 2023 The trial has been completed (End Date: 22 Mar 2023), according to European Clinical Trials Database record.